-
141
-
142
COSMIC project: consensus on the objectives of the metabolic syndrome in clinic
Published 2018-10-01“…Juan Pedro-Botet,1 Juan F Ascaso,2,3 Vivencio Barrios,4,5 Alejandro De la Sierra,6 Javier Escalada,7,8 Jesús Millán,9 Jose M Mostaza,10 Pablo Pérez-Martínez,8,11 Xavier Pintó,8,12 Jordi Salas-Salvadó,8,13 Pedro Valdivielso14 1Lipids and Vascular Risk Unit, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Endocrinology and Nutrition Service, Hospital Clínico, Universitat de Valencia, Valencia, Spain; 3INCLIVA Research Institute, Diabetes and Metabolic Diseases Ciber (Networked Biomedical Research Centres – CIBERDEM), Carlos III, Valencia, Spain; 4Cardiology Service, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain; 5Department of Medicine, Universidad Católica de Murcia (UCAM), Murcia, Spain; 6Internal Medicine Service, Hospital Mutua de Terrassa, Department of Medicine, Universidad de Barcelona, Spain; 7Department of Endocrinology and Nutrition, Clínica Universitaria de Navarra, IdiSNA; 8CIBEROBN “Physiopathology of Obesity and Nutrition”, Carlos III Health Institute, Spain; 9Lipid Unit, Department of Internal Medicine, Hospital Universitario General Gregorio Marañón, Universidad Complutense, Madrid, Spain; 10Lipid and Arteriosclerosis Unit, Internal Medicine Service, Hospital Carlos III, Madrid, Spain; 11Lipid and Arteriosclerosis Unit, Hospital Universitario Reina Sofía, IMIBIC/University of Cordoba, Cordoba, Spain; 12Lipids Unit, Department of Internal Medicine Hospital Universitario de Bellvitge, Universidad de Barcelona, Barcelona, Spain; 13Nutrition Unit, Hospital Universitari Sant Joan de Reus, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili; 14Internal Medicine Service, Department of Medicine and Dermatology, Hospital Universitario Virgen de la Victoria, Málaga Biomedicine Institute (IBIMA), Universidad de Málaga, Málaga, Spain Abstract: Metabolic syndrome (MetS), a disorder with a high and growing prevalence, is a recognized risk factor for cardiovascular disease (CVD) and type 2 diabetes. …”
Get full text
Article -
143
Psychosocial interventions reduce cortisol in breast cancer patients: systematic review and meta-analysis
Published 2023-06-01Get full text
Article -
144
A polydiagnostic approach to cognitive deficits in schizophrenia
Published 2021-04-01“…Disclosure This work was supported by the Government of Navarra (grants 17/31, 18/41, 87/2014) and the Carlos III Health Institute (FEDER Funds) from the Spanish Ministry of Economy and Competitivity (14/01621 and 16/02148). …”
Get full text
Article -
145
-
146
Metal mixtures and DNA methylation measures of biological aging in American Indian populations
Published 2023-08-01Get full text
Article -
147
-
148
-
149
-
150
Transcriptomic and Genetic Associations between Alzheimer’s Disease, Parkinson’s Disease, and Cancer
Published 2021-06-01Get full text
Article -
151
Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
Published 2023-07-01“…Alberto Cordero,1,2 Regina Dalmau González-Gallarza,3 Lluis Masana,4– 6 Valentín Fuster,7,8 Jose Mª Castellano,7,9,10 José Emilio Ruiz Olivar,11 Ilonka Zsolt,11 Antoni Sicras-Mainar,12 Jose Ramón González Juanatey2,13,14 1Cardiology Service, San Juan University Hospital, Alicante, Spain; 2Cardiovascular Diseases Network Research Center (CIBERCV), Madrid, Spain; 3Cardiology Service, La Paz University Hospital, Madrid, Spain; 4Sant Joan University Hospital, Vascular Medicine and Metabolism Unit, Reus, Spain; 5Pere Virgili Institute of Health Research (IISPV), Reus, Spain; 6Center for Biomedical Research Network on Diabetes and Associated Metabolic Diseases (CIBERDEM), Reus, Spain; 7National Center for Cardiovascular Research (CNIC), Carlos III Health Institute, Madrid, Spain; 8Mount Sinai Medical Center, New York, NY, USA; 9Integral Center for Cardiovascular Diseases (CIEC), Montepríncipe University Hospital, HM Hospitales Group, Madrid, Spain; 10School of Medicine, CEU San Pablo University, Madrid, Spain; 11Corporate Medical Affairs, Ferrer, Barcelona, Spain; 12Health Economics and Outcomes Research Department, Atrys Health, Madrid, Spain; 13Cardiology Service, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain; 14Santiago de Compostela Health Research Institute (IDIS), Santiago de Compostela, SpainCorrespondence: Antoni Sicras-Mainar, Atrys Health SA, Calle Príncipe de Vergara, 132, planta 1, Madrid, 28002, Spain, Tel +34 917 819 465, Fax +34 915 776 744, Email ihernandez@atryshealth.comPurpose: The aim of this study was to estimate health-care resources utilization, costs and cost-effectiveness associated with the treatment with CNIC-Polypill as secondary prevention of atherosclerotic cardiovascular disease (ASCVD) compared to other treatments, in clinical practice in Spain.Patients and Methods: An observational, retrospective study was performed using medical records (economic results [healthcare perspective], NEPTUNO-study; BIG-PAC-database) of patients who initiated secondary prevention between 2015 and 2018. …”
Get full text
Article -
152
-
153
-
154
-
155
HIF1α-dependent uncoupling of glycolysis suppresses tumor cell proliferation
Published 2024-04-01Get full text
Article -
156
The role of veterinarians in zoonosis prevention: Advising families of immunocompromised children with pets
Published 2024-06-01Get full text
Article -
157
-
158
A self-repair history: compensatory effect of a de novo variant on the FANCA c.2778+83C>G splicing mutation
Published 2023-07-01Get full text
Article -
159
The relevance of EGFR, ErbB receptors and neuregulins in human adipocytes and adipose tissue in obesity
Published 2022-12-01Get full text
Article -
160
Should we suspect primary aldosteronism in patients with hypokalaemic rhabdomyolysis? A systematic review
Published 2023-09-01Get full text
Article